STOCK REPORT · 140410 · KOSDAQ
Mezzion Pharma
Star it to add it to your market report.
Overall grade
32 pointsLower-middle bandOverall 32 points · Grade C, 18 points to Grade B
Financial summary
Mezzion Pharma (140410) has an overall grade of C from financial statements, with a score of 32 out of 100. Category scores are Earnings 36 (Grade C), Financial health 25 (Grade D) and Dividends 36 (Grade C). Data as of Oct 23, 2026.
Reported figures: ROE -203.14%, Debt-to-equity ratio 470.09%, Current ratio 57.29%, Dividend streak 0 yrs. Valuation: PBR 103.25x, Market cap ₩1.8T.
4 of the 9 graded metrics have values in this update.
The share price was collected from the Korea Exchange on Oct 23, 2026. PER and PBR divide the market cap by the year-end figures. How the grades are calculated is set out in the grading methodology.
This summary restates reported financial figures. It does not forecast share prices or returns.
Valuation
52-week range
Now at 9% of rangeWithin their own 52-week ranges, 25.3% of major Korean stocks sit lower than this one.
About these metrics
- PBR
- Price to book ratio (market cap ÷ net assets). Below 1x, the market value is below book value.
- Market cap
- Share price × shares outstanding. The value the market puts on the whole company.
- 52-week high
- The highest share price over the past year.
- 52-week low
- The lowest share price over the past year.
Scores by category
Each metric out of 100 · category score is the average of threeEarnings
40% of overall · Lower-middle bandEach metric is scored out of 100, and the 36 above is the average of the three scores.
Metrics with values1 of 3
Metrics shown as - in the table are not measured in this update, because the data has no such item.
About these metrics
- ROE
- Return on equity. How much profit the company made on its own capital (equity).
- Operating margin
- Operating profit as a share of revenue: what the core business keeps.
- Revenue growth
- How much revenue changed compared with a year earlier.
Financial health
35% of overall · Bottom bandEach metric is scored out of 100, and the 25 above is the average of the three scores.
Metrics with values2 of 3
Metrics shown as - in the table are not measured in this update, because the data has no such item.
About these metrics
- Debt-to-equity ratio
- Liabilities as a share of equity. A lower ratio means the company relies less on debt.
- Current ratio
- Assets that can turn into cash within a year, as a share of debts due within a year. At 100% or more they cover those debts.
- Interest coverage
- How many times operating profit covers interest expense. Below 1x, operating profit does not cover interest.
Dividends
25% of overall · Lower-middle bandEach metric is scored out of 100, and the 36 above is the average of the three scores.
Metrics with values1 of 3
Metrics shown as - in the table are not measured in this update, because the data has no such item.
About these metrics
- Dividend yield
- Dividends paid over a year as a share of the current share price.
- Payout ratio
- The share of profit paid out as dividends. A very high ratio can be hard to keep up.
- Dividend streak
- How many years in a row the company has paid a dividend.
Metric scores are shown rounded to one decimal place, so a category score can differ by up to 1 point from a plain average of the three shown.
Strengths · Weaknesses
Strengths
No notable strengths among metrics with values
Weaknesses
- Low profit relative to equity (ROE -203.14%)Below the median 9.2% of 63 Healthcare stocks
- Heavy debt burden (debt-to-equity ratio 470.09%)Above the median 54.9% of 64 Healthcare stocks
- Tight short-term liquidity (current ratio 57.29%)
Only metrics that stand out as clearly good or weak against general benchmarks are listed. Where a comparison is possible, the position against the median of stocks in the same sector is shown too. The stock count on each sector line covers only stocks with that metric, so it differs by metric.
Metrics that moved the overall score
- Operating margin0.0 pts
- Revenue growth0.0 pts
- Interest coverage0.0 pts
- Dividend yield0.0 pts
- Payout ratio0.0 pts
- Dividend streak-3.3 pts
- Current ratio-4.1 pts
- Debt-to-equity ratio-4.7 pts
- ROE-5.3 pts
Metric scores run up to 100, and the middle score is 50. If all nine metrics scored 50, the overall score would also be 50. Each bar is the contribution of one metric: how far its score sits from the 50 baseline, converted by that metric weight. Right means it raised the overall score, left means it lowered it.
Adding the nine contributions above to the baseline gives 32.6 points, and this stock's overall score is 32. The overall score is calculated from unrounded metric scores and then truncated, while the contributions here are rounded to one decimal place, so the two can differ by up to 1 point. Metrics that are not measured values still carry a contribution, because their scores did go into the overall score and hiding them would hide part of the basis of the grade.
| Metric | Mezzion Pharma | Sector median | Rank in sector |
|---|---|---|---|
| PER | - | 34.3x | |
| PBR | 103.3x | 6.7x | |
| ROE | -203.1% | 9.2% | |
| Operating margin | - | 13.0% | |
| Debt-to-equity ratio | 470.1% | 54.9% | |
| Dividend yield | - | 0.7% |
Grey values on the right are sector medians
Metric ranks in sector
Closer to 1st sits further left- PBRRank 64 of 65, top 98%
- ROERank 62 of 63, top 98%
- Debt-to-equity ratioRank 62 of 64, top 97%
On the rank strip, the left end is 1st. PER, PBR and debt-to-equity ratio are ranked from the lowest value, and ROE, operating margin and dividend yield from the highest.
Healthcare stocks close in market cap rank
Sector medians cover the 71 Healthcare stocks listed on Jupick. Typical levels differ by sector, so this is reference information for a simple comparison and not a basis for investment decisions.
About these metrics
- PER
- Price to earnings ratio (market cap ÷ annual net profit). A lower value means a lower price relative to profit.
- PBR
- Price to book ratio (market cap ÷ net assets). Below 1x, the market value is below book value.
- ROE
- Return on equity. How much profit the company made on its own capital (equity).
- Operating margin
- Operating profit as a share of revenue: what the core business keeps.
- Debt-to-equity ratio
- Liabilities as a share of equity. A lower ratio means the company relies less on debt.
- Dividend yield
- Dividends paid over a year as a share of the current share price.
Where this score sits
4.2% of the major stocks graded by Jupick score lower than this. Stocks in the same Grade C: 126.
- S172.8%
- A14524.2%
- B28948.2%
- CThis stock12621%
- D233.8%
The Grade C band runs from 30 to 49 points, 20 points wide. This stock's 32 points sit 2 points above the lower boundary, and 18 points remain to 50, where Grade B starts.
Within the Healthcare sector alone, it ranks No. 69 of 71 stocks with an overall score, and the median overall score of the sector is 60.
Unlike metric values, the overall score uses the same baseline for every market and currency, so Korean and US stocks share one sample. The grade boundaries of 85, 70, 50 and 30 points apply equally to every stock, so the counts above are how the sample actually splits at those boundaries. Because one point can decide a grade, two stocks with different grades can be closer in score than two stocks with the same grade. The shares and ranks here describe only the major stocks Jupick covers, not every listed stock.
Stocks with similar score profiles
| Stock | Earnings | Financial health | Dividends |
|---|---|---|---|
| Mezzion Pharma (140410, this stock) | 36 | 25 | 36 |
| CISU Specialty Chemical | 39 | 29 | 36 |
| CSimmtech | 36 | 32 | 39 |
| CWoori Technology, Incorporation | 37 | 36 | 36 |
| CHJ Shipbuilding & Construction | 48 | 26 | 36 |
Mezzion Pharma (140410) has category scores of Earnings 36 · Financial health 25 · Dividends 36. These are the four major stocks graded in all three categories whose profiles come closest, and no category differs by more than 12 points.
The three scores are given by Jupick from public financial metrics, each out of 100. A similar profile means similar grading results only. It does not mean the share prices move alike.
Ratios as amounts
Base ₩10,000Every ratio metric of this stock, restated on the same amount. If each line used a different base, the amounts could not be compared, so every line starts from ₩10,000.
For every ₩10,000 of equity: yearly net loss ₩20,310.ROE -203.1%
- For every ₩10,000 of equitydebt owed ₩47,010
- For every ₩10,000 of debt due within a yearassets turning into cash within a year ₩5,730
- For ₩10,000 of book equitymarket value ₩1,033,000
The ₩10,000 base is an assumption chosen for easy reading, not this company's actual revenue or equity. The values multiply the ratios shown as they are and round to the nearest won, so they can differ from the source by a few won. Metrics that make no sense as amounts are left out: values that are not measured, values that cannot be confirmed as measured, and loss-making cases where the base amount does not hold.
Metrics that decide the grade
Overall 32 · Grade CThe overall score recalculated with just one of the nine metrics set to the middle score of 50. Only one metric changes at a time, and the other eight stay as they are.
With any single metric at 50, the overall score stays in Grade C.
The metric closest to a boundary is ROE. With only this metric at 50, the overall score would be 37.3, 12.7 points from the 50 point boundary. Earnings · metric 10 · contribution -5.3
The scores above add up this stock's metric scores again with one of them set to 50. They are not new grades, and this stock's grade stays at C. Metric scores and contributions are rounded to one decimal place, so a change within 1 point of a boundary is not reported as a grade change. Changing two or more metrics at once was not calculated.
Where the share price enters the grade
The grade above turns 9 metrics into scores and combines them. Counting how many of them use the share price shows whether the grade moves when the price moves.
The 9 graded metrics stay the same when the share price moves.
- Earnings grade metrics (3)Does not use the share price0 of 3 metrics use the share price
- Financial health grade metrics (3)Does not use the share price0 of 3 metrics use the share price
- Dividends grade metrics (3)Does not use the share price0 of 3 metrics use the share price
- PER and PBRCome from the share price but are not scoredNot graded
For Korean stocks, Dividend yield is taken as stated in the disclosure, so it is not recalculated when the share price changes. What changes the grade is the next financial filing, not the share price.
Stocks with a value for each metric
The grade above uses 9 metrics. Each line shows how many major stocks have a value for that metric, so you can tell whether a blank is specific to this stock or common to most stocks.
4 of the 9 graded metrics have values.
- ROEHas a value567 of 600 stocks have a value
- Operating marginNot reported562 of 600 stocks have a valueMost stocks have a value
- Revenue growthNot reported570 of 600 stocks have a valueMost stocks have a value
- Debt-to-equity ratioHas a value559 of 600 stocks have a value
- Current ratioHas a value545 of 600 stocks have a value
- Interest coverageNot reported278 of 600 stocks have a valueMore than half of stocks have no value
- Dividend yieldNot reported519 of 600 stocks have a valueMost stocks have a value
- Payout ratioNot reported507 of 600 stocks have a valueMost stocks have a value
- Dividend streakHas a value595 of 600 stocks have a value
Blank metrics on this stock: 5. Most other stocks have values for 4 of them, so those wait for this stock's filing.
Position in the market distribution
Korean stocksWhere the value of Mezzion Pharma sits when the Korean stocks on Jupick are lined up from the smallest value, ignoring sector. Left is smaller, right is larger, and the shaded part is the middle half.
The thin lower axis counts the position again within the same sector (Healthcare) only. All metrics with a lower axis sit in the same band as the whole market.
- PBR103.3x
- ROE-203.1%
- Debt-to-equity ratio470.1%
Mezzion Pharma metrics with no position on this page. Jupick does cover them, but they could not be lined up this time. The reason is given next to each.
- PER Could not be lined up this time
- Operating margin Could not be lined up this time
- Dividend yield Could not be lined up this time
Won and dollar stocks have different metric levels, so they are counted in separate samples. This is only where a value sits in a line-up, not a sign of good or bad and not an investment judgement. Stocks without the metric, and loss-making stocks where PER or PBR does not hold, are left out of the sample. The remaining sample size is shown on each line. The sector axis is not drawn when the same-currency, same-sector sample has fewer than 8 stocks.
Korean and US yardsticks
Healthcare sectorWhere one value of Mezzion Pharma sits among Korean stocks in the same sector, and among US stocks. Only ratio metrics that compare across currencies are used.
All 3 compared metrics sit in the same band on both yardsticks.
Only metrics with at least 8 stocks on both sides are compared.
Next
Investment notice
For information only. Not investment advice. Grades and figures are reference material calculated from public information. They do not ask anyone to trade a security and make no promise of returns. You are solely responsible for your investment decisions and their results, and Jupick accepts no legal liability for them.